The effect of HemoHIM supplement for the prevention of ventilator associated pneumonia

Evaluation of the effect of HemoHIM supplement for the prevention of ventilator associated pneumonia in critically ill patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150221021159N6

Enrollment

Registered

2021-04-04

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventilator associated pneumonia. Ventilator associated pneumonia

Interventions

Intervention 1: Intervention group: In addition to the standard care conducted in ICU for preventing ventilator-associated pneumonia, a packet of HemoHIM supplement containing 20 cc of herbal extract

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Gaining informed consent Adult patients undergoing mechanical ventilation for more than 48 hours

Exclusion criteria

Exclusion criteria: Diagnosis of acute respiratory distress syndrome or pneumonia at intensive care unit (ICU) admission Existence of immunodeficiency and leukopenia

Design outcomes

Primary

Measure	Time frame
Incidence of ventilator associated pneumonia. Timepoint: Evaluation of the occurrence of ventilator associated pneumonia daily, during 14 days after study recruitment. Method of measurement: Calculate the clinical pulmonary infection score (CPIS) table.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShadi Farsaei

Esfahan University of Medical Sciences

Farsaei@pharm.mui.ac.ir+98 31 3792 7071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026